Urinary thallium levels may reflect recent or chronic exposure and the presence of thallium in urine after acute exposure may persist for up to several weeks. Concentrations less than 5 µg/L are unlikely to cause adverse health effects while concentrations greater than 500 µg/L have been associated with clinical poisoning. After severe thallium poisoning reported symptoms have varying times of onset and include gastroenteritis, multi-organ failure and neurologic injury. Peripheral neuropathy and alopecia are well-documented effects of acute and chronic exposure. Human health effects from low level thallium exposure are unknown.
See Compliance Statement B
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.